Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-effect study of oral ModraDoc006 with ritonavir in cancer patients
NL-OMON46116Completed
- Sponsor
- Modra Pharmaceuticals
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ModraDoc006 and ritonavir in cancer, sponsored by Modra Pharmaceuticals. Primary endpoint: Effect of high-fat meal on docetaxel exposure. Started May 2017; status: completed.
02
Drugs
ModraDoc006ritonavir
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON46116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46116.